摘要
目的:观察在超排卵中促性腺激素释放激素(GnRH)拮抗剂的垂体抑制效果及其安全性。方法:选取2006年3月至4月在本中心行体外受精-胚胎移植(IVF/ICSI)的32例患者,分为试验组(11例)和对照组(21例)。试验组应用GnRH拮抗剂抑制垂体,对照组应用GnRH激动剂降调节垂体(长方案)。2组均于注射绒毛膜促性腺激素(HCG)日检测血清黄体生成素(LH)、雌二醇(E2)水平,并观察比较2组注射HCG日血清LH、E2的水平。结果:注射HCG日试验组的血清LH水平[(3.24±3.11)IU/L]与对照组[(3.18±2.83)IU/L]相比差异无统计学意义(P>0.05),但均起到了抑制内源性的LH峰的效果;试验组血清E2水平[(993.93±685.47)IU/L]明显低于对照组[(1720.93±625.69)IU/L],差异有统计学意义(P<0.05)。结论:GnRH拮抗剂抑制垂体方案能有效地抑制内源性的LH峰,在临床应用上与GnRH激动剂垂体降调节长方案一样取得了相同的垂体抑制效果。GnRH拮抗剂降低了注射HCG日血清E2含量,因此可能减少卵巢过激的发生。
Aim： To observe the effect on pituitary suppression and safety by using gonadotrophin releasing hormone antagonist （GnRH antagonist） in Controlled Ovarian Hyperstimulation （COH）. Methods：All 32 patients who underwent IVF or intracytoplasmic sperm injection （ICSI） during 2006.3 -2006.4 in our center were analyzed and randomly divided into two groups： study group and control group. During hormonal pituitary suppression, 11 cases in the study group re- ceived GnRH antagonist, and 21 cases in the control group received GnRH agonist, namely long protocol. Serum LH and E2 levels were measured on the day of HCG injection. Results ： The study group [ （3.24 ± 3.11 ） IU/L ] and the control group [ （3.18 ± 2.83） IU/L] both had effects on inhibition of endogenous LH peak, but there was no significant difference between the two groups. However, serum E2 level in the control group E （1 720.93 ± 625.69）IU/L] was much lower than that of the study group [ （993.93 ± 685.47） IU/L ] （ P 〈 0.05 ）. Conclusion ： Similar to the long protocol, GnRH antagonist pituitary suppression protocol can inhibit the endogenous LH peak and has the same effect on pituitary suppression. Furthermore, GnRH antagonist contributes to lower serum E2 levels and then reduce occurrence of OHSS.
出处
《郑州大学学报（医学版）》
CAS
北大核心
2009年第1期166-169,共4页
Journal of Zhengzhou University(Medical Sciences)
关键词
超排卵
促性腺激素释放激素拮抗剂
促性腺激素释放激素激动剂
卵巢过度刺激综合征
controlled ovarian hyperstimulation
gonadotrophin releasing hormone antagonist GnRH antagonist
gonadotrophin releasing hormone antagonist agonist
ovarian hyperstimulation syndrome
